Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Summer;3(3):105-111.
Epub 2017 Jun 13.

Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications

Ketan Thanki  1 , Michael E Nicholls  1 , Aakash Gajjar  1 , Anthony J Senagore  1 , Suimin Qiu  2 , Csaba Szabo  3 , Mark R Hellmich  1 , Celia Chao  1
Affiliations

Consensus Molecular Subtypes of Colorectal Cancer and their Clinical Implications

Ketan Thanki et al. Int Biol Biomed J. 2017 Summer.

Abstract

The colorectal cancer (CRC) Subtyping Consortium has unified six independent molecular classification systems, based on gene expression data, into a single consensus system with four distinct groups, known as the Consensus Molecular Subtypes (CMS); clinical implications are discussed in this review. This article is based on a literature review relevant to the CMS of CRC indexed in PubMed (US National Library of Medicine) as well as the authors' own published data. The CMS were determined and correlated with epigenomic, transcriptomic, microenvironmental, genetic, prognostic and clinical characteristics. The CMS1 subtype is immunogenic and hypermutated. CMS2 tumors are activated by the WNT-β-catenin pathway and have the highest overall survival. CMS3 feature a metabolic cancer phenotype and CMS4 cancers have the worst survival and have a strong stromal gene signature. The Consensus Molecular Subtypes of CRC may better inform clinicians of prognosis, therapeutic response, and potential novel therapeutic strategies.

Keywords: classification; clinical; colorectal cancer; molecular subtypes.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST M.R.H., C.S., and C.C. are officers and/or shareholders of CBS Therapeutics Inc., an UTMB spin-off company involved in research and development of H2S biosynthesis inhibitors for the therapy of cancer. The other authors declare no potential conflicts of interest.

References

    1. No authors noted. Cancer facts and statistics. Date Accessed: January 23, 2017. Available from: www.cancer.org/research/cancer-facts-statistics.

    1. Welch HG, Robertson DJ. Colorectal cancer on the decline–Why screening can’t explain it all. N Engl J Med. 2016;374:1605–1607. - PubMed
    1. Edge SB, Byrd SR, Compton CC, Fritz AG, Greene FL, Trotti A., III . Colon and rectum. New York: Springer; 2010.
    1. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108–1113. - PubMed
    1. Budinska E, Popovici V, Tejpar S, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol. 2013;231:63–76. - PMC - PubMed

LinkOut - more resources